Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma

  title={Extracellular signal-regulated kinase 1 and 2 in cancer therapy: a focus on hepatocellular carcinoma},
  author={Amir Mehdizadeh and Mohammad hosein Somi and Masoud Darabi and Mortaza Jabbarpour-Bonyadi},
  journal={Molecular Biology Reports},
Extracellular signal-regulated kinases (ERK) pathway plays a crucial role in cancer cell survival and proliferation. This signaling pathway has been related to epithelial to mesenchymal transition and drug resistance in hepatocellular carcinoma (HCC) cells, which is a common challenge in chemotherapy. Consequently, mediators of this pathway have recently been considered as novel therapeutic targets in HCC. In this review the impact of ERK1 and ERK2 as major components of ERK signaling pathway… 
Liposome-mediated RNA interference delivery against Erk1 and Erk2 does not equally promote chemosensitivity in human hepatocellular carcinoma cell line HepG2
The data show that liposomal siRNA-mediated down-regulation of Erk1/2 can lead to potent chemosensitizing effects in HepG2 cells, and a higher chemosensitivity following Erk2 down- regulation than ErK1 down- Regulation may be associated with the higher expression of ErK2 in human HCC.
Involvement of N-glycan in Multiple Receptor Tyrosine Kinases Targeted by Ling-Zhi-8 for Suppressing HCC413 Tumor Progression
LZ-8, a medicinal peptide from Ganoderma lucidium, was effective in suppressing cell migration of HCC413, by decreasing the amount and activity of various RTKs, which led to the suppression of downstream signaling including phosphorylated JNK, ERK involved in HCC progression.
The p53/miR-34a/SIRT1 Positive Feedback Loop in Quercetin-Induced Apoptosis
Background: The anti-tumor effects of quercetin have been reported, but the underlying molecular mechanisms remain to be elucidated. The aim of present study was to explore the role of miRNA in the
p53‐independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells
It is shown that the upregulation of Noxa is critical for cisplatin‐induced apoptosis in p53‐null HNSCC cells, and ATF3 and ATF4 are important regulators that induce NoxA by cisPlatin treatment in a p 53‐independent manner.
microRNA‐95 knockdown inhibits epithelial–mesenchymal transition and cancer stem cell phenotype in gastric cancer cells through MAPK pathway by upregulating DUSP5
Evidence was obtained demonstrating that miR‐95 knockdown or DUSP5 upregulation exerted an inhibitory effect on the EMT process, cellular processes, and tumor growth.
Baicalein, a Natural Anti-Cancer Compound, Alters MicroRNA Expression Profiles in Bel-7402 Human Hepatocellular Carcinoma Cells
Modulation of miRNA expression may be an important mechanism underlying the anti-hepatoma effects of baicalein.
14-3-3η, a novel growth-promoting factor in hepatocellular carcinoma, not only in tumor but also in intratumoral vessels
Please cite this article as: Shen, J., Jiang, F., Yang, Y., Huang, G., Pu, F., Liu, Q., Chen, L., Ju, L., Lu, M., Zhou, F., Zhang, C., Luo, X., Yang, X., Jiao, C., Li, X., Li, Z., Li, Y., Zhang, J.,
Pinocembrin-Enriched Fractions of Elytranthe parasitica (L.) Danser Modulates Apoptotic and MAPK Cellular Signaling in HepG2 Cells.
The findings reveal that pinocembrin glycoside and chrysin are bioactive phytochemicals contributing to the potent anti-hepatocarcinoma effects on HepG2 cells, indicating that bioactive EP fractions could be used as a therapeutic agent for effective HCC therapy.
Interleukin‐10 negatively modulates extracellular signal‐regulated kinases 1 and 2 in aorta from hypertensive mouse induced by angiotensin II infusion
It is suggested that IL‐10 negatively modulates ERK 1/2 activation and prevents hypercontractility during Ang II‐induced hypertension.


Targeting the ERK signaling pathway in cancer therapy
The possibility that combination of ERK pathway inhibitors and conventional anticancer drugs (cytotoxic agents) provides an excellent basis for the development of new chemotherapeutic strategies against cancer is discussed.
Reversing multidrug resistance in hepatocellular carcinoma cells by inhibiting extracellular signal-regulated kinase/mitogen-activated protein kinase signaling pathway activity
The inhibition of ERK signaling pathway activity may be an important method to reverse the MDR of HCC cells, but is not unique.
Role of the ERK1/2 pathway in tumor chemoresistance and tumor therapy.
ERK1/2 blockade prevents epithelial-mesenchymal transition in lung cancer cells and promotes their sensitivity to EGFR inhibition.
It is demonstrated that extracellular signal-regulated kinase (ERK) 1/2 (mitogen-activated protein kinase 3/1, MAPK3/1) signaling plays a key role in directing the mesenchymal character of NSCLC cells and that blocking ERK signaling is sufficient to heighten therapeutic responses to EGF receptor (EGFR) inhibitors.
Resistance to Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors Correlates with Up-Regulation of the MEK/Extracellular Signal-Regulated Kinase Pathway in Hepatocellular Carcinoma Cells
It is shown that combining two chemically distinct MEK inhibitors enhanced growth inhibition and apoptosis compared with the single agents and provided preclinical evidence suggesting that the status of the MEK/ERK pathway in patients may predict response to MEK /ERK-targeted therapeutics.
Down-regulation of extracellular signal-regulated kinase 1/2 activity in P-glycoprotein-mediated multidrug resistant hepatocellular carcinoma cells.
QRT-PCR analysis demonstrated that the ERK1 and ERK2 mRNA expression increased apparently in HepG2/ADM cells and decreased significantly in SMMC7721/ ADM cells, which might be a potential drug target for circumventing MDR HCC cells.
Activation of mitogen‐activated protein kinases/extracellular signal‐regulated kinases in human hepatocellular carcinoma
MAPK/ERK activation in human HCC may play an important role in multistep hepatocarcinogenesis, especially in the progression of HCC; at least in part, through cyclin D1 up‐regulation primarily induced by MAPK/ ERK via c‐Fos.
MAPK signaling in cisplatin-induced death: predominant role of ERK1 over ERK2 in human hepatocellular carcinoma cells.
It is proposed that ERK2-specific targeting could improve the efficacy of cisplatin therapy by increasing ERK1 prodeath functions, after a transient or stable specific inhibition by RNA interference in humans and knockout mice.
Increased MAPK expression and activity in primary human hepatocellular carcinoma.
Because of the important role that the MAPK pathway plays in cellular growth and differentiation, overexpression of MAPK may be of critical importance to the formation and maintenance of human hepatocellular carcinoma.
The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.